Suburban Research Associates is seeking participants ≥ 18 years of age for a generalized anxiety disorder study.
Generalized Anxiety Disorder – Media, PA
Age Range:
18 to 100
Gender:
Male and Female
Location:
Media, Pennsylvania
Compensation* :
up to $100 per appointment
About the Study
This study is approximately 10 weeks (about 2 and a half months) long and includes 9 appointments at our office in Media, PA. The purpose of the study is to evaluate the effectiveness of an investigational medication compared to placebo for the treatment of generalized anxiety disorder when taken with another anti-anxiety medication. This is called adjunctive therapy, or add-on therapy.
There is no cost for participating in our research study. You will be compensated up to $100 per appointment for your time and travel dedicated to completing the clinical trial.
Qualifications
- ≥ 18 years of age
- Are you currently taking at least one of the following medications for your anxiety- paroxetine, venlafaxine XR, duloxetine, escitalopram, buspirone
- Are experiencing symptoms of generalized anxiety disorder
*Please note, other qualifications apply
FEATURED STUDIES
Lyme Disease Prevention
Suburban Research Associates in West Chester, PA is conducting a research study focused on Lyme disease prevention.
Diabetic Kidney Disease
Suburban Research Associates is seeking adults living with Type 2 diabetes who have been diagnosed with diabetes-related kidney damage and
Type 1 Diabetes & Insulin Management
Suburban Research Associates is seeking adults living with Type 1 diabetes who may be interested in participating in a clinical
Major Depressive Disorder
Suburban Research Associates is conducting a new research study evaluating an investigational medication for adults living with Major Depressive Disorder
Tophaceous Gout
Suburban Research Associates is enrolling adults with Tophaceous Gout for a research study testing a new medication compared to allopurinol,
Gout and high uric acid
Suburban Research Associates is enrolling adults to test a potential new treatment to help lower uric acid levels and reduce